JMP Securities Maintains Outperform on Athira Pharma, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler maintains an 'Outperform' rating on Athira Pharma (NASDAQ:ATHA), but has lowered the price target from $20 to $19.

August 11, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Athira Pharma's price target has been lowered from $20 to $19 by JMP Securities, though the 'Outperform' rating is maintained.
The lowering of the price target by JMP Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential upside, which could counterbalance the negative impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100